ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ UNG THƯ BIỂU MÔ TẾ BÀO GAN BẰNG PHƯƠNG PHÁP DEB-TACE TẠI CẦN THƠ NĂM 2023-2025

Abstract

Background: Liver cancer ranks first in both incidence and mortality rates among cancers in Vietnam, according to GLOBOCAN 2022. Due to its slow and silent progression, the disease is often detected at a stage beyond the possibility of surgical treatment. Therefore, non-surgical treatment methods such as DEB-TACE are often chosen. Objective: To investigate the clinical and paraclinical characteristics as well as the treatment outcomes of hepatocellular carcinoma (HCC) after drugeluting bead transarterial chemoembolization (DEB-TACE) using the mRECIST criteria. Materials and Methods: A prospective, randomized, non-controlled clinical trial was conducted on 55 patients diagnosed with HCC based on the diagnostic criteria set by the Ministry of Health of Vietnam. Response assessment after TACE was conducted according to the mRECIST scale at 3-month and 6month intervals. Results: The average age was 68.49 ± 10.61 years, with a male-to-female ratio of 32/23. Risk factors included hepatitis B (60%) and hepatitis C (32.7%). Prior interventions included surgery (3.6%), radiofrequency ablation (5.5%), and TACE (41.8%), while 40% had no prior intervention. The most common tumor size was 5.1–8 cm (41.8%). Complete response for target lesions at 3 months was 45.5%. Post-procedure complications were mostly grade 1 (69.1%). Conclusion: DEB-TACE is effective in short-term tumor control when evaluated using mRECIST.